Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Graypoint LLC

Graypoint LLC cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,108 shares of the biopharmaceutical company’s stock after selling 238 shares during the period. Graypoint LLC’s holdings in Regeneron Pharmaceuticals were worth $1,502,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Mizuho Securities USA LLC boosted its stake in Regeneron Pharmaceuticals by 625.5% during the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after purchasing an additional 51,162 shares during the period. Tri Locum Partners LP lifted its stake in shares of Regeneron Pharmaceuticals by 104.5% in the 2nd quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock worth $18,410,000 after acquiring an additional 8,949 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after acquiring an additional 2,828 shares during the period. Simplify Asset Management Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 50.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after acquiring an additional 3,231 shares during the period. Finally, Catalytic Wealth RIA LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $1,334,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 5.0 %

Regeneron Pharmaceuticals stock opened at $696.88 on Friday. The firm has a market cap of $76.58 billion, a PE ratio of 17.25, a P/E/G ratio of 2.19 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The firm’s 50 day moving average price is $751.44 and its two-hundred day moving average price is $962.58. Regeneron Pharmaceuticals, Inc. has a twelve month low of $691.00 and a twelve month high of $1,211.20.

Wall Street Analyst Weigh In

A number of analysts recently commented on REGN shares. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Wells Fargo & Company dropped their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday. JPMorgan Chase & Co. dropped their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. Sanford C. Bernstein dropped their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday. Finally, Morgan Stanley dropped their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,037.33.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.